June 2005 in “Journal of Investigative Dermatology” A bull with a gene mutation was asymptomatic, synthetic retinoids cause hair loss, and new therapeutic targets were identified for skin diseases.
April 2018 in “Journal of Investigative Dermatology” Higher levels of nidogen1 and type IV collagen are found in basal cell carcinoma compared to normal skin.
4 citations
,
January 2018 in “Cancer treatment and research” The document concludes that systemic therapy is becoming more important in treating head and neck cancer, with new treatments showing promise.
4 citations
,
January 2016 in “Dermatology practical & conceptual” A man developed a rare skin condition after a hair transplant surgery.
56 citations
,
April 2015 in “American journal of medical genetics. Part A” Patients with Bohring-Opitz syndrome and ASXL1 mutations need regular kidney ultrasounds to check for tumors.
9 citations
,
June 2011 in “American Journal of Dermatopathology” Molluscum contagiosum can occur in epidermoid cysts, especially with prolonged steroid use.
2 citations
,
September 2018 in “JAAD case reports” A rare type of skin cancer with mucosal involvement was partially treated but eventually relapsed.
17 citations
,
October 2001 in “British Journal of Ophthalmology” Intralesional cidofovir might be a good alternative treatment.
Androgen receptor overexpression can increase prostate cancer cell growth even without hormones.
July 2025 in “Scientific Reports” Six key genes can predict bladder cancer outcomes and may serve as prognostic biomarkers.
19 citations
,
January 2014 in “International Journal of Medical Sciences” Abnormal activation of hair follicle stem cells and Wnt/β-catenin signaling contributes to sebaceous neoplasms.
14 citations
,
December 1998 in “British Journal of Cancer” Truncated hHb1 keratin may play a role in breast cancer cell transformation.
New cancer drugs can cause skin side effects like rashes, dry skin, hair changes, and nail problems.
September 2006 in “Dermatologic Surgery” Some aggressive scalp cancers are hard to treat and can be deadly, even when removed with specialized surgery.
23 citations
,
December 2013 in “Molecular cancer therapeutics” Breast cancer treatments work better with AR activation, improving results and reducing side effects.
3 citations
,
April 2012 in “Cancer research” Mouse skin cancer progression involves a unique group of cells marked by ABCG2 and MTS24.
2 citations
,
November 2019 in “Cancer reports” The Wnt signaling pathway is not a major factor in the development of keratoacanthoma, a type of skin tumor.
1 citations
,
October 2009 in “Cancer Epidemiology Biomarkers & Prevention” Cancer prevention is crucial, with a focus on research and improved screening methods.
1 citations
,
July 2014 in “International Journal of Dermatology” A cancer patient developed a type of hair loss after starting a cancer drug called vandetanib.
11 citations
,
November 2015 in “Carcinogenesis” Deleting TNFα gene reduces skin cancer risk in certain mice.
135 citations
,
October 1999 in “Journal of Cell Science” Overexpressing PKCα in mice skin increases inflammation but doesn't affect tumor growth.
February 2026 in “Frontiers in Medicine” Personalized sonidegib dosing can effectively treat Gorlin-Goltz syndrome with fewer side effects.
May 2019 in “CINECA IRIS Institutial Research Information System (University of Genoa)” MITF+ melanoma patients are more likely to have multiple melanomas and unique skin patterns.
April 2026 in “Research Square” January 2026 in “International Journal of Molecular Sciences” Hedgehog pathway inhibitors could be effective in treating melanoma.
June 2025 in “Histopathology” Epithelial elements in superficial angiomyxomas are non-neoplastic growths mimicking embryogenesis.
June 2011 in “Oncology times” New treatments are making advanced prostate cancer management more complex but also more hopeful.
August 2024 in “Dermatology and Therapy” Vorasidenib can cause unusual hair growth.
January 2005 in “Enlighten: Publications (The University of Glasgow)” Melanocyte pathology requires keratinocyte hyperplasia and regulation dysfunction.
2 citations
,
November 2024 in “In Silico Pharmacology”